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Background: Honokiol (HK) is a natural bioactive compound with proven antineoplastic
properties against melanoma. However, it shows very low bioavailability when administered
orally. Alternatively, topical administration may offer a promising route. The objective of the
current study was to fabricate HK transfersomes (HKTs) for topical treatment of melanoma.
As an ultradeformable carrier system, transfersomes can overcome the physiological barriers
to topical treatment of melanoma: the stratum corneum and the anomalous tumor micro
environment. Moreover, the immunomodulatory and stemness-regulation roles of HKTs were
the main interest of this study.
Methods: TFs were prepared using the modified scalable heating method. A three-factor,
three-level Box–Behnken design was utilized for the optimization of the process and
formulation variables. Intracellular uptake and cytotoxicity of HKTs were evaluated in
nonactivated and stromal cell–activated B16F10 melanoma cells to investigate the influence
of the complex tumor microenvironment on the efficacy of HK. Finally, ELISA and Western
blot were performed to evaluate the expression levels of TGF-β and clusters of differentia
tion (CD47 and CD133, respectively).
Results: The optimized formula exhibited a mean size of 190 nm, highly negative surface
charge, high entrapment efficiency, and sustained release profile. HKTs showed potential to
alleviate the immunosuppressive characteristics of B16F10 melanoma in vitro via down
regulation of TGF-β signaling. In addition, HKTs reduced expression of the “do not eat me”
signal — CD47. Moreover, HKTs possessed additional interesting potential to reduce the
expression of the stem-like cell marker CD133. These outcomes were boosted upon combi
nation with metformin, an antihyperglycemic drug recently reported to possess different
functions in cancer, while combination with collagenase, an extracellular matrix–depleting
enzyme, produced detrimental effects.
Conclusion: HKTs represent a promising scalable formulation for treatment of the aggressive
B16F10 melanoma, which is jam-packed with immunosuppressive and stem-like cell markers.
Keywords: honokiol, melanoma, transfersomes, heating method, tumor microenvironment,
immunosuppressive, stem-like cell

Introduction
Recently, great advances in the field of pharmaceutical biotechnology have been
achieved. However, cancer and infectious diseases still occupy the second rank in
threats to humanity after cardiovascular diseases. Skin cancer (melanoma)
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originates from melanin-producing melanocytes, present
ing the subtype with the highest mortality and highest
potential to metastasize throughout the systemic circula
tion and lymphatic system traveling to reach distant
organs, such as the brain, lungs, and liver.2–5
Nowadays, surgical resection is considered the first line
of melanoma therapy, in addition to traditional chemother
apy, radiotherapy, immunotherapy, and biological therapy.6
The failure of most therapeutic agents is due to the
immunosuppressive7–9 and stem-like10,11 nature of B16F10
melanoma cells, in addition to the complex structure of
tumor tissue. The complexity of tumor tissue is due to the
tumor microenvironment (TME) which includes a variety of
cellular components that contribute to tumor invasion,
metastasis, and drug resistance.12 On one hand, B16F10
melanoma cells exhibit high levels of the “do not eat me”
ligand CD47. This is a ligand for SIRPα, an immunoinhi
bitory receptor, which is expressed on myeloid cells, includ
ing macrophages and dendritic cells. The binding of CD47
to SIRPα is a tumor-immunoevasion strategy via inhibition
of phagocytosis of tumor cells by immune-system cells.7–9
In addition, B16F10 melanoma cells express high levels of
CD133 (Prom1), which is a membrane glycoprotein char
acteristic of cancer stem cells (CSCs). CSCs exhibit high
potential for tumor growth and metastasis, inhibition of
apoptosis, recurrence, and resistance to different therapeutic
approaches.10,11 The key cellular players in the TME are
tumor-associated fibroblasts (TAFs) and tumor-associated
macrophages (TAMs).13 TAFs perform multiple activities
in tumor formation. They induce the proliferation of tumor
tissue contribute to the secretion of collagen and tumorassociated proteins (growth factors), which constitute the
dense extracellular matrix (ECM). They also regulate the
innate and adaptive immune system by secreting TGF-β,
leading to the suppression of antitumor immunoresponses.14
Furthermore, TAFs contribute to the regulation of polariza
tion of TAMs to their immunosuppressive phenotype M2.15
This phenotype of TAMs maintains several protumoral
functions represented in supporting the progression of
tumor growth by increasing the secretion of growth factors
and facilitating angiogenesis and metastasis.16 Various stra
tegies have been employed for TME remodeling, eg, col
lagenase has been utilized as an ECM-depleting enzyme to
digest collagen, facilitating the diffusion of therapeutic
agents in tumor tissue.17–19 Furthermore, metformin, an
FDA-approved first-line treatment of type2 diabetes, is cur
rently receiving great attention for its anticancer effects and
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potential for targeting CSCs.20 It has been reported that
metformin mediates macrophages polarization from the
M2 to M1 phenotype21,22 and possesses a suppressive role
on TGF-β signaling.23–26
Lately, plant-derived compounds have been proven to
have safe pharmacological chemotherapeutic action
against various cancer types compared to synthetic che
motherapeutics, with lower toxicity.27
A natural bioactive compound derived from species of
the Magnoliaceae family(Magnolia officinalis, M. grand
iflora, and M. obovata), HK has proven antineoplastic
properties against melanoma,28,29 pancreatic,30 lung,31
colorectal,32 and ovarian cancer,33 head and neck squa
mous-cell carcinoma,34 breast cancer,35 and even hepato
cellular carcinoma.36 HK has proved to have a lot of
striking anticancer activities: it can inhibit angiogenesis,
provide direct cytotoxicity, potentiate apoptosis, inhibit
multiple-drug resistance, and deregulate cancer cell–sig
naling pathological pathways involved in growth and
malignancy, which it can target.28,37 HK shows very low
oral bioavailability (5%), due to the first-pass effect and
low absorption. Alternatively, topical application may
offer a promising route, as it is patient-compliant and it
can augment HK therapeutic action.6,38,39 Nevertheless,
topical delivery is still challenging, due to the presence
of physiological barriers: the stratum corneum, the anom
alous TME, and the interstitial matrix.40,41 Consequently,
several nanocarriers have been developed to circumvent
the stratum corneum, whereby they can deliver hydrophilic
compounds and biomacromolecules to deeper skin layers,
achieve a sustained local effect, and enhance topical drug
delivery and thus provide high drug bioavailability.42,43
The structure of transfersomes (TFs) resembles liposomes
in composition — both formed of phospholipids — but
TFs show superior advantages due to the presence of an
edge activator in their composition.44 An edge activator is
a single-chain surfactant that destabilizes the
vesicle’s phospholipid bilayer and increases its deform
ability, rendering it an ultradeformable elastic vesicle45
that can squeeze itself through the intercellular space of
the stratum corneum and penetrate deeper skin layers.44
Volatile organic solvents like chloroform, ether, or
methanol are used in most TF-preparation methods, such
as solvent evaporation46 and thin lipid–film hydration.47
This leads to the presence of residues of these organic
solvents, which may cause toxicity and affect the stability
of the final TF preparation. Accordingly, it is advised to
avoid the usage of toxic solvents in preparation
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procedures.48,49 This has led to the evolution of the heat
ing method, which can be conducted without the utiliza
tion of organic solvents. This method was introduced by
Mozafari et al, and involves the application of heat, not
lower than the phase-transition temperature (Tc) of the
lipids, as below this temperature lipids are present in the
gel state and cannot form a closed continuous bilayered
structure.50 The heating method has proved to be
a scalable, safe, less time-consuming, and more cost-effec
tive method of nanovesicular preparation.51 Using drugdelivery systems of these plant-derived compounds formu
lated by a technique based on green synthesis is an eco
friendly and safe therapeutic modality for human use that
can be applied to large-scale production with low cost.52
The aim of this study was to follow a green optimized
fabrication process of an HK TF–nanodelivery system in
order to improve HK bioavailability and skin penetrability.
Furthermore, the potential effect on modulating the TME
of B16F10 melanoma cells was evaluated in monotherapy
or in combination with two TME-remodeling agents —
metformin and collagenase — focusing on evaluation of
the immunosuppressive and stem-like cell characteristics
of B16F10 melanoma cells in response to mono- or com
binatorial therapies via evaluation of TGF-β, CD47, and
CD133.

Methods
Materials
HK of purity 98% (HPLC) was purchased from Stanford
Chemicals, sodium deoxycholate (SDc) from Janssen
Pharmaceuticals, soy lecithin and cholesterol from Alfa
Aesar, metformin hydrochloride from Sohan Healthcare,
and collagenase from Sigma-Aldrich, Germany.
Fluorescein isothiocyanate was obtained from Biotium,
absolute ethanol from Medico, and HPLC-gradeacetoni
trile from Thermo Fisher Scientific. All other chemicals
were of analytical grade. Murine melanoma (B16F10,
CRL6475), fibroblast (L929, CCL1), and macrophage
(RAW264.7, TIB71) cell lines were purchased from
the American Type Culture Collection.

Experimental Design
In the present study, three-factor, three-level Box–Behnken
design was used to investigate the influence of formulation
and process factors and interaction effects on TF charac
teristics. This design is an optimum approach for ascer
taining the effects of formulation/process factors
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(independent variables) and their associated effects on
measured responses (dependent variables).53 Based on
preliminary studies, drug amount (X1), stirring speed
(X2), and homogenization speed (X3) were chosen as the
independent variables. Particle size (PS;Y1), PDI (Y2),
Zeta-potential (ZP; Y3), and drug entrapment efficiency
(EE%) (Y4) were selected as the dependent variables.
Table 1 shows the levels of the independent variables
and the constraints of the obtained responses/dependent
variables. A design matrix comprised of 15 experimental
runs with three central points was obtained, as listed in
Table 2. After polynomial equations relating the dependent
and independent variables had been generated, the process
was optimized.

Method of Fabrication
Fifteen TF formulations (Table 2) were fabricated using the
modified heating method.54 Firstly, lecithin (180 mg) and
SDc (20 mg) were hydrated individually in 2 mL PBS (pH
7.4) for 1 hour at room temperature, then placed into
a preheated mixture of glycerol (3% v/v) and HK (different
amounts) at 70°C while stirring at different speeds (1,000,
1,250, and 1,500 rpm) for 1 hour on a hot-plate magnetic
stirrer (MSH-20D, 280 V, 50/60 Hz, 660 W, Daihan
Scientific). Then, the mixture was left to cool for 30 minutes,
leaving the vesicles to anneal and stabilize. Later, the for
mulations were homogenized using a WiseTis homogenizer
(280 W, 50/60 Hz, Daihan Scientific) for 5 minutes, with 60
seconds on and 30 seconds off cycles. Finally, the vesicles
were stored in a refrigerator at 4°C for further investigations.
The whole fabrication process was performed in a sixbaffled homemade vessel (Figure 1) simulating the specially
designed glass bottle introduced by Mozafari.55
Table 1 Independent and dependent variables of Box–Behnken
design utilized to prepare honokiol-loaded transfersome
formulations
Independent variables (factors)
X1: HK amount (mg)
X2: Stirring speed (rpm)
X3: Homogenization speed (rpm)
Dependent variables (responses)

Levels
10
1,000

25
1,250

40
1,500

0

5,000

10,000

Desirability constraints

Y1: Particle size (nm)
Y2: Polydispersity index

Minimize
Minimize

Y3: Zeta-potential (mV)
Y4: Entrapment efficiency (%)

Maximize
Maximize
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Table 2 Experimental runs, independent variables and observed responses of 15 honokiol transfersome formulations prepared
according to Box–Behnken design
X1 (mg)

X2 (rpm)

X3 (rpm)

Y1 (nm)

Y2

Y3 (mV)

Y4 (%)

HKT1

25

1,000

10,000

213.3±2.86

0.472±0.020

−40.00±0.96

60.00±1.24

HKT2

40

1,000

5,000

306.5±0.64

0.422±0.034

−35.37±1.06

76.24±1.62

HKT3
HKT4

10
40

1,000
1,250

5,000
10,000

475.3±3.82
139.1±1.85

0.488±0.011
0.413±0.014

−38.83±1.55
−39.33±1.65

49.46±0.87
62.60±0.97

HKT5

25

1,250

5,000

234.2±1.02

0.465±0.003

−50.20±2.45

75.00±1.36

HKT6
HKT7

10
10

1,250
1,250

10,000
0

131.3±1.54
566.8±1.63

0.385±0.011
0.549±0.011

−39.23±1.77
−44.70±1.22

32.60±0.88
74.40±1.57

HKT8
HKT9

40
25

1,250
1,500

0
10,000

463.4±1.77
166.7±0.81

0.435±0.010
0.444±0.024

−42.50±1.61
−37.47±1.27

89.90±0.96
76.57±0.47

HKT10

25

1,250

5,000

211.9±3.78

0.469±0.008

−52.93±3.05

77.50±0.99

HKT11
HKT12

25
40

1,250
1,500

5,000
5,000

220.6±1.06
314.3±1.87

0.48±0.0150
0.364±0.030

−49.86±2.12
−36.53±0.15

75.75±1.78
84.38±1.69

HKT13

25

1,500

0

416.2±1.46

0.503±0.011

−44.57±1.52

81.23±0.75

HKT14
HKT15

10
25

1,500
1,000

5,000
0

252.20±0.97
506.0±2.46

0.565±0.007
0.588±0.019

−43.00±0.34
−42.93±2.37

67.99±0.69
84.64±0.73

Notes: X1, HK amount; X2, stirring speed; X3, homogenization speed; Y1, particle size; Y2, polydispersity index; Y3, Zeta potential; Y4, entrapment efficiency (%).
Abbreviation: HKTs, HK-loaded transfersomes.

Mean Particle Size, Particle-Size
Distribution, and ZP
PS and PDI of all formulations were analyzed using
a Zetasizer Nano ZS (Malvern Instruments) using dynamic
light scattering. ZP was determined from electrophoretic
mobility with the same instrument by injecting the samples
into a universal folded capillary cell with platinum electrodes
at both ends.56 Freshly prepared TF dispersions were diluted
tenfold by deionized water, then PS, PDI, and ZP were

measured. Measurements were performed three times and
mean PS, PDI, and ZP were calculated.

Determination of HK-Entrapment
Efficiency
HK entrapment in the TF vesicles was determined using the
indirect method. Briefly, a known volume of the sample was
centrifuged at 15,000 rpm for 2 hours at 4°C (Centurion ProResearch K241R), the supernatant was then separated, and

Figure 1 The six-baffled homemade glass vessel simulating Mozafari’s glass bottle.
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the absorbance of the free HK was determined with UVvisible spectroscopy (JASCO V-630) at a wavelength with
maximum absorbance at 219 nm. EE% was calculated:57
EE% ¼

Total HK

Free HK in supernatant
� 100
Total HK

(1)

Optimization of Process Variables
Based on the results obtained, optimization of the variables
was conducted using Design-Expert 11 (Stat-Ease) based on
the criterion of desirability. The desirability function was intro
duced by Derringer and Suich.58 It relies upon the concept that
the quality of a novel formulation developed, which has many
features, is totally unacceptable if one of the features is outside
the desirable limit.59 The desirability function is used to corro
borate compliance with the criteria selected for all involved
responses and to provide the best value of compromise in
a desirable joint response.60 This can be achieved by convert
ing the multiple responses evaluated into a single one, combin
ing the individual responses into a composite function,
followed by its optimization. To confirm the validity of the
optimization process, the suggested HK transfersome (HKT)–
optimized formula (HKTopt) with the highest desirability and
predicted levels of formulation and process variables was
prepared. It was then characterized, and observed values of
the responses were compared to the predicted values. The
HKTopt formula was then subjected to further investigations.

Transmission Electron Microscopy
The morphology of the HKTopt formula was investigated
using transmission electron microscopy (TEM). A drop of
the TF suspension was placed on a carbon-coated copper
grid and then air-dried at room temperature. The sample
was examined at 80 kV with a Hitachi H600.

Deformability Index
For determination of the elasticity of TFs in comparison to
liposomes (of relevant composition), the HKTopt and the
corresponding liposomal suspension were extruded
through a polycarbonate membrane of pore size 50 nm
(Thermo Fisher Scientific) applying a constant pressure of
250 kPa (Haug Kompressoren). Deformability-index
values were calculated as an indicator of elasticity:61,62
D¼

J
tðrv

r p Þ2

(2)

where D is the deformability index (mL/second), J the
quantity of dispersion extruded (mL), t is the extrusion

International Journal of Nanomedicine 2021:16

time (seconds), rv the vesicle size after extrusion (nm), and
rp the pore size of the extrusion membrane (nm).

Fourier-Transform Infrared Analysis
To assess interactions among HK, lecithin, and SDc,
Fourier-transform infrared (FTIR; JASCO FTIR-6200)
spectroscopy was performed for these components indivi
dually and the HKTopt formula in the 4,000–400 cm−1
wavelength range at room temperature with a resolution
of 4 cm−1.

In Vitro Release Study
For the determination of HK in vitro release kinetics from
TFs, 500 µg HK of the HKTopt and the same amount of
free HK in ethanol (1.64 mg/mL) as control were used to
compare between the release kinetics of the pure drug and
the HKTopt. Each of the HKTopt and the free HK was filled
in a dialysis bag made of semipermeable cellulose mem
brane with molecular weight 12–14 kDa (Spectrum
Medical). Each dialysis bag was incubated in a beaker
containing a dissolution medium formed of 50 mL 0.5%
sodium lauryl sulphate in PBS (pH 7.4 to achieve sink
conditions). The whole set was immersed in a shaking
water bath (Sci FineTech, 220 V, 50 Hz) at 37°C±1°
C and 100 rpm. The experiment was conducted for 24
hours. At predetermined time points, the samples were
withdrawn and replaced by an equal volume of the freshly
prepared medium. The concentration of the released HK
was quantified spectrophotometrically at 219 nm, and the
cumulative release profile with time was calculated. This
experiment was performed in triplicate.63

Establishment of Tumor-Associated
Macrophage– and Tumor-Associated
Fibroblast–Activated B16F10 Melanoma
Culture
For the establishment of TAM-activated and TAF-acti
vated melanoma cultures, B16F10 melanoma cells were
cultured in 50% RAW246.7 macrophages or L929 fibro
blast-derived conditioned media in fresh culture media for
48 hours. The conditioned media was obtained from con
fluent cultures of RAW246.7 macrophages or L929 fibro
blasts. Successful activation of B16F10 melanoma cells
was assessed via evaluation of the concentration of TGF-β
from culture supernatants of activated and nonactivated
melanoma cells via ELISA. TGF-β secreted by TAMs
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and
TAFs
promotes
tumorigenesis.64–67

several

hallmarks

of

Intracellular Uptake of
Fluorescein-Loaded TFs and Mechanism
of Endocytosis
For determination of the intracellular concentration of TFs,
a modified protocol by Sebak et al68 was followed.
A noncytotoxic concentration of 250 μg/mL fluoresceinloaded TFs was incubated with the activated and nonacti
vated B16F10 melanoma cells under 37°C and 5% CO2.
After the predefined incubation of 24 hours, the culture
medium containing the noninternalized TFs was discarded.
Cells were then washed three times with PBS and fresh
media added for the measurement of the fluorescence inten
sity of the internalized TFs using a multimode microplate
reader (Victor 3 V 1420, PerkinElmer) at excitation/emis
sion wavelength of 485/535 nm. A freshly constructed cali
bration curve of fluorescein-loaded TFs in complete culture
medium was utilized for the calculation of the intracellular
concentration of TFs.
For determination of the mechanism of endocytic
uptake, activated and nonactivated B16F10 melanoma
cells were pretreated with endocytic inhibitors in their
respective concentrations for 1 hour prior to the addition
of the TFs. A 15×103 μM quantity of sodium azide, 103 μM
methyl-β-cyclodextrin (MβCD), and 450 μM sucrose were
utilized for evaluation of energy dependence, cholesterol
dependence, and clathrin-pit dependence of TF uptake,
respectively. Similarly, 20 μM nystatin and 50 μM amilor
ide were utilized as inhibitors of caveolin-dependent endo
cytosis and micropinocytosis, respectively.68–71

Cytotoxicity of HKTs
For determination of the cytotoxicity of HKTs on activated
and nonactivated B16F10 melanoma, a standard MTT
assay was used for 1–100 μg/mL of TFs-loaded HK after
a predefined incubation time of 24 hours.72 For determina
tion of the cytotoxicity of the combination therapy, cells
were pretreated with the noncytotoxic concentration of
metformin (100 μg/mL) or collagenase (50 μg/mL) for
24 hours prior to the addition of HKTs.

Enzyme-Linked Immunosorbent Assay
TGF-β was analyzed from the cell-culture supernatant
according to the manufacturer’s protocol using a mouse
transforming TGF-β ELISA kit (MBS160136) from
MyBioSource.

Sodium Dodecyl Sulfate–Polyacrylamide Gel
Electrophoresis and Western Blot (WB) Analysis
CD47 and CD133 (Prom1) were analyzed from cell lysates
via SDS-PAGE and WB according to the previously pub
lished, well-established protocol in the lab of Professor
Laila Rashed, Biochemistry Department, Faculty of
Medicine, Cairo University.73,74 CD47 (Thermo Fisher
Scientific, 14–0471-82), CD133 (ThermoFisherScientific,
14–1331-82), and β-actin (ThermoFisherScientific, MA1140) monoclonal antibodies were used for the analysis.
Bands for CD47, CD133, and β-actin proteins were visua
lized by enhanced chemiluminescence (ECL Plus) and
quantified relative to β-actin using densitometry and
Molecular Analyst software (Bio-Rad).

Statistical Analysis
All experiments were conducted at least three times, and
results are expressed as means ± SE. One-way and twoway ANOVA or t-test analyses were utilized for statistical
evaluation of the data using GraphPad Prism 8.3.
Significance was regarded as P<0.05. IC50 was determined
by nonlinear regression analysis of the cytotoxicity data.

Results and Discussion
Analysis of Responses
After fabrication of the 15 HK transfersome (HKT) for
mulations mentioned in Table 2 by the modified heating
method, the impact of the three independent variables —
HK amount (X1), stirring rate (X2), and homogenization
speed (X3) — on PS (Y1), PDI (Y2), ZP (Y3), and EE%
(Y4) was evaluated using Design Expert 11.

Biomarker Analysis

Effect of Process Variables on Particle
Size and PDI

For evaluation of the alteration of different biomarkers in
response to the proposed treatment options, activated and
nonactivated B16F10 melanoma cells were treated with

Y1 ranged from 131.3±1.54 nm to 506±2.46 nm, corre
sponding to HKT6 and HKT15, respectively, as shown in
Table 2. Vesicular Y1 was greatly affected by X3 (P<0.0001)
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as speed increased from 0 to 10,000 rpm and decreased
sharply from 506±2.46 nm to 131.3±1.54 nm, indicating
that homogenization speed was a key parameter in control
ling Y1. Figure 2A shows the response surface plot of the
measured Y1 of the prepared formulations versus X2 and X3
respectively. The polynomial equation used relating the par
ticle size to the independent variables was:
Y1 ¼ 222:23 25:29X1 43:96X2 162:75X3
þ 57:72X1 X2 þ 27:80X1 X3 þ 10:80X2 X3 þ 57:22X1
þ 57:62X2 þ 45:70X3
(3)
The findings obtained can be explained by the increase
inthe mechanical and hydraulic shear as a result of enhan
cing the homogenization speed, which in turn causes
a dramatic decrease in PS.75 Similar findings were gained
by Song et al, who discussed the effect of high-pressure
homogenization on the PS of soy protein–isolate suspen
sions and found reductions in mean PS from 3,331.3 to
146.7 and 135.8 nm after being processed by high-pressure
homogenization for 30 passes at 137 and 207 MPa,
respectively.76 Stirring speed produced similar effect on
PS whereas smaller PS was obtained at higher stirring
speed (1,000-1500).This goes in accordance with previous
studies elaborating the effect of stirring speed on surface

area77 and droplet size.78 As shown in Figure 2A, the
lowest PS, 131.3±1.54 nm (HKT6), was achieved at the
maximum applied stirring and homogenization speeds —
1,500 and 10,000 rpm, respectively. The results proved
that there was no significant effect of drug amount on PS
(P>0.05), consistent with a study on paromomycin-loaded
solid-lipid nanoparticles.79 Regarding interactions among
the independent variables, statistical interpretation of the
design coefficients indicated that the combination of both
HK amount (X1) and stirring speed (X2) had a synergistic
effect on particle size of the TF vesicles. The PDI ranged
from 0.364±0.030 to 0.588±0.019, represented by HKT12
and HKT15, respectively, as shown in Table 2. The poly
nomial equation relating PDI (Y2) to the independent
variables can be shown as such:
Y 2 ¼ 0:4713 0:0441X1 0:0118X2 0:0451X3
0:0337X1 X2 þ 0:0355X1 X3 þ 0:0142X2 X3
0:0339X1 þ 0:0223X2 þ 0:0081X3

(4)

The PDI was used as a an indication of size distribution,80
where a value of 0 was considered as a completely homo
geneous system and a value of 1 indicated a highly hetero
geneous distribution of vesicles.81 In reference to Table 2, all
samples showed relatively small PDI, indicating their homo
geneity and the reliability of all measurements. It was clear

Figure 2 3-D surface response plots showing the relative effects of independent variables on (A) particle size, (B) PDI, (C) Zeta-potential, (D) drug EE%, and (E)
desirability.
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that the homogenization speed had a significant impact on
particle-size distribution (P=0.0161). The negative of X3
indicated a negative relationship between homogenization
speed and PDI, indicating more uniform size distribution
and smaller PDI values with higher homogenization speed.
Zidan et al affirmed similar outcomes.82 It was also found
that drug amount had a significant effect on PDI (P=0.0175):
its value was diminished by increasing the drug amount, as
shown in Figure 2B. It was noticed that good PDI values
were obtained in most of the formulations without the use of
either sonication or extrusion, the most effective techniques
for particle size–distribution reduction. This indicates that the
modified heating method is an efficient preparation method
that can be scaled up without using expensive organic sol
vents or energy-consuming processes.

(P=0.0184). The polynomial equation relating particle
size to the independent variables was:

Effect of Variables on ZP

Effect of Process Variables on
HK-Entrapment Efficiency

ZP ranged from −35.37±1.06 to −52.93±3.05 mV for
HKT2 and HKT10, respectively (Table 2), showing that
the TF preparations possessed good stability as ZP >30
mV indicates the stability of the formulations.56 ZP
was significantly affected by homogenization speed

Y3 ¼

51 þ 1:50X1 0:555X2 þ 2:33X3 þ 0:7525X1 X2
0:575X1 X3 þ 1:04X2 X3 þ 6:18X1 þ 6:38X2
þ 3:37X3
(5)

The increase in homogenization speed from 0 to
10,000 rpm resulted in ZP decreasing from −52.93±3.05
to −35.37±1.06 mV, as shown in Figure 2C. This suggests
that increasing the energy input in the system led to a
decrease in the surface charge. In a study by Severino et
al, it was observed that higher homogenization speed led
to a reduction in ZP from 24 to 0 mV compromising the
dispersion
stability
and
promoting
particle
83
agglomeration.

The hydrophobic drug HK was entrapped in lecithin nano
vesicles containing SDc as an edge activator. In the experi
mental design, we kept the quantities of lecithin and SDc
fixed and varied the loading amount of HK to determine

Figure 3 Desirability ramps for the independent variables, with the predicted value of each measured response.
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the effect of drug amount on EE%. EE% ranged between
32.6%±0.88% to 89.9%±0.96%, which were the values for
HKT6 and HKT8, respectively, as shown in Table 2.
Linear regression showed significance (P=0.0008), and
the linear model was suggested to best describe the effect
of variables on Y4 as the difference between the adjusted
R2 and predicted R2 being <0.2. Equation (6) describes the
effect of the independent variables on EE%:
Y 4 ¼ 71:22 þ 11:08X1 þ 4:98X2

12:3X3

(6)

Drug amount had a significant effect on HK EE%
(P=0.0026). The positive X1 in the equation indicated that
increasing the drug amount resulted in an increase in EE%.
Despite that our finding contradicts those observed in a
previous study in which the EE% of resveratrol in solid
lipid nanoparticles was observed to decrease as drug amount
increases.84 This could be explained on the basis of the
hydrophobicity of HK whereas the lipid bilayer represents
a better solubilizing vehicle to HK than the external phase
composed mainly of PBS (Figure 2D).85 Statistical analysis
also revealed a significant effect of homogenization on drug
EE% (P=0.0013), and the negative X3 indicated an inverse
effect of homogenization on EE%. This might be due to the
ample shearing effect produced by the application of homo
genization that caused disruption of the TF structure, leading
to leakage of the drug and thus diminishing drug
entrapment.86 These results are in agreement with a study
on Pseudoephedrine HCl loaded nanoliposomes for trans
dermal delivery.87 In the current study, the maximum HK EE
% (89.9%) was achieved by incorporation of 40 mg of drug
in the TFs without the application of homogenization.

Optimization of HKTs Formulation
The aim of the optimization process of HKTs formulation was
to determine the levels of the factors studied required to
produce a formulation of the highest-possible quality.
According to the Box–Behnken model and based on criterion
of desirability, the optimum values of the studied variables are
suggested in Figure 2E. Desirability-function values range
between 0 to 1. The function seeks the most favorable and
compromising point in the design space that fulfils the goal for
each dependent variable. The suggested values of the indepen
dent variables are shown in the optimization ramp (Figure 3).
The desirability value of the suggested HKTopt was 0.751.
To confirm the optimization process, the HKTopt was
prepared and characterized, then the actual observed
responses were compared to the predicted responses of
Y1, Y2, Y3, and Y4 that are listed in Table 3. As seen
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from the table, there was reasonably good agreement
between predicted and observed responses. The adequate
predictive performance of the design model justifies its
application in the rationalization of an optimal formula
and the validity of the optimization design.

TEM of the Optimized HKT Formulation
Morphological examination of HKTopt vesicles was done
using TEM, as illustrated in Figure 4. As seen in the figure,
it was noted that spherical, well-defined, uniformly sized, and
unilamellar vesicles existed as discrete dispersed entities.

Deformability Test
TF vesicles’ hallmark is their flexibility compared to lipo
somes, enabling the TFs to pass easily through the biological
membranes.88 Therefore, the HKTopt was formed of lecithin
(the phospholipid) and SDc (the edge activator) at a ratio of
9:1, and its corresponding liposomal suspension consisting
of lecithin (the phospholipid) and cholesterol, instead of
SDc, at a ratio of 9:1 were selected to be tested for elasticity.
The test was conducted by extruding each of the vesicular
suspensions through a polycarbonate membrane of pore size
50 nm. The TFs exhibited a higher deformability index (13.9
±0.9 mL/s) than the liposomes (3.94±1.2 mL/s) according to
the deformability index as per equation (2). This is attributed
to the presence of the edge activator in the TF structure,
which rendered it higher elasticity than liposomes. The
deformability index (D-value) of the TF preparation was in
strong agreement with a previous study on the preparation of
TFs encapsulating sildenafil, which found that the D-value
of the best formula containing the optimum phospholipid:
surfactant ratio was 14.88 mL/s.89 Another study done by
Salama et al on olanzapine-loaded TFs containing SDc as
edge activator showed that a phospholipid:edge-activator
molar ratio of 10:1 achieved the highest deformability
index in comparison to higher (100:1) or lower (5:1) ratios,
Table 3 Predicted and observed responses of the optimized
transfersomal formulation
Independent

X1 (mg)

X2

variables

X3 (rpm)

(rpm)
32.86

1,300

5,562

Response

Y1 (nm)

Y2

Y3 (mV)

Y4 (%)

Predicted
Observed

208.5
189.9

0.431
0.471

−47.98
−53.4

76.65
78.92±1.22

±1.06

±0.0001

±1.63
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as increasing the concentration of SDc in which the phos
pholipid:SDc molar ratio equaled 5:1 led to diminishing
vesicle deformability owing to the steroid-like structure of
the SDc, becoming bulkier and resulting in less flexible
vesicles.90

Fourier-Transform Infrared Analysis
The FTIR spectra of HK, lecithin, SDc, and HKTopt are
shown in Figure 5. In the HK spectrum, the peaks in the
range of 3,550–3,100 cm−1 were due to OH vibration.
A band was located at 1,601cm−1, representing the alkene
C=C present in HK.91 The intense bands at 1,495 and 1,426 
cm−1 were assigned to the aromatic ring-stretching vibrations
of the HK molecule. Other bands were found at 1,205 and
908 cm−1 (C–O) and 994 and 824 cm−1 (C–C).92 In lecithin,
the broad band centered at 3,318 cm−1 was assigned to OH
stretching, the principal bands at 2,861 cm−1 and 2,927 cm−1
corresponding to symmetric and antisymmetric stretching,
respectively, in the CH2 groups of alkyl chains, in addition
to the scissoring vibrations at 1,404 cm−1 representing the
CH2 groups. The characteristic phosphate-group vibrational
band assigned to the PO2− antisymmetric stretching mode
was centered at 1,232 cm−1 and the PO2− symmetric stretch
ing mode at 1,083 cm−1.93 Regarding the SDc spectrum, the
three distinctive features at 2,927, 2,861, and 1,556 cm−1 are

infrared-absorption bands corresponding to CH stretching
vibration and COO− stretching vibration.94 The FTIR spectra
of HKTopt showed that the peaks of the individual samples
were shielded or absent and new peaks appeared at 3,268 
cm−1 and 1,636 cm−1 indicating the occurrence of molecular
interactions among the components during TF preparation.

In Vitro Release Study
The release profile (Figure 6) showed that only 50.1%
±2.673% and 53.34%±2.535% of HK was released from
the HKTopt after 24 and 48 hours, respectively, in contrast
to the ethanolic solution of free drug, which showed
97.629%±3.354% release after 1 hour, indicating the sus
tained-release effect of the HKTopt. Similar patterns of
sustained release were observed for lidocaine, a local
anaesthetic, from transferosomes in comparison to the
release profile of the free drug.63

Extent and Mechanism of Intracellular
Uptake of TFs in Nonactivated and TAMor TAF-Activated Melanoma Cells
The extent of TF accumulation in B16F10 melanoma cells
increased upon their incubation with stromal cell–derived
conditioned media (Figure 7A). Similar results of higher
uptake and retention of nanosystems in activated versus

Figure 4 Transmission electron microscopy of the optimized formula at 80 KV, with magnification (A) 80,000× and (B) 25,000×.
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Figure 5 FTIR spectra of pure honokiol, lecithin, sodium deoxycholate, and the optimized formula.

nonactivated cells have been reported for TAFs versus normal
fibroblasts95 and hypoxic versus normoxic phenotypes of
breast cancer cells.96 The variation in the extent of intracellular
accumulation of TFs can be explained on the basis of the
mechanism of endocytic uptake. Treatment of B16F10 cells
with sodium azide, an ATP-depleting agent, prior to the incu
bation of TFs caused a reduction in the extent of their accu
mulation, especially in nonactivated and TAF-activated cells
(Figure 7B and D, respectively) suggesting the involvement of
energy-dependent pathways in TFs uptake.68 Similarly,
amiloride, which inhibits macropinocytosis,70 caused a very
significant reduction in TF cellular concentration levels.
Nystatin, which inhibits caveolin-dependent endocytosis,71
did not result in a significant change in intracellular concentra
tion of the TFs. Regarding the involvement of cholesteroldependent endocytosis, as suggested from the effect of

International Journal of Nanomedicine 2021:16

pretreatment with MβCD, a reduction in TF intracellular
uptake was observed in both nonactivated and TAF-activated
cells (Figure 7B and D, respectively). Surprisingly, the extent
of TF intracellular uptake increased in the case of TAMactivated cells (Figure 7C) upon utilization of MβCD and
sucrose, which inhibit cholesterol-dependent68 and clathrindependent97 endocytosis, respectively. This suggests that
blocking one endocytic mechanism could facilitate the uptake
of TFs via an alternative pathway, which could be more
efficient and/or more rapid.98

Cytotoxicity of HKTs in Activated and
Nonactivated Melanoma Cells
The effect of HKTs on the viability of B16F10 melanoma
cells when cultured in fresh medium or conditioned medium
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Figure 6 In vitro release profile of honokiol, showing the cumulative percentage released from the optimized formula in PBS (pH 7.4) and the ethanolic solution of the pure
form (n=3).

derived from a culture of RAW264.7 macrophages and L929
fibroblasts was assessed. HK has been previously reported to
possess appealing anticancer effects in hepatocellular
carcinoma,99 triple-negative breast cancer,100 hepatoma,101
oral squamous-cell carcinoma,102 lung,103 thyroid,104 and
ovarian cancer,105 and osteosarcoma.106 Upon activation of
melanoma cells with conditioned media derived from stro
mal-cell cultures, a significant increase in IC50 was observed
(Figure 8). This contradicts the observed increase in the
concentration of TFs in activated melanoma cells. This
could be attributed to the development of resistance mechan
isms upon induction of cell–cell interactions when cells were
incubated with cytokine-rich conditioned media, as could be
observed from the levels of TGF-β in TAM- and TAF-acti
vated melanoma cells (Figure 10). TGF-β is a potent protu
morigenic and immunosuppressive cytokine that regulates
multiple functions in the TME.64–67

Intracellular Uptake and Cytotoxicity of
TFs upon Pretreatment with TMERemodeling Agents (Metformin and
Collagenase)
Pretreatment with either metformin or collagenase did not
result in any contribution to the extent of the intracellular
accumulation of the TFs in nonactivated or TAF-activated
B16F10 melanoma cells (Figure 9A). However, collagenase
pretreatment significantly increased the intracellular concen
tration of TFs in TAM-activated B16F10 melanoma cells. This
could be explained by the ability of collagenase to digest dense
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ECM components, eg, collagen which could have
facilitated uptake of the TFs. Enhancement in the uptake of
magnetic nanoparticles in pancreatic cancer cells has been
reported with pretreatment with collagenase.107 A similar
observation was recorded for permeability of nanoparticles in
3-D spheroids.18
Unexpectedly,the susceptibility of nonactivated mela
noma cells to HK-mediated cytotoxicity decreased signifi
cantly upon pretreatment with collagenase (Figure 9B).
However, this could be explained on the basis of the ability
of collagenase to increase TGF-β activation,108 consistent
with our results elaborated in Figure 10, which has multiple
implications
in
cancer
resistance
to
different
chemotherapeutics.109 On the contrary, metformin and col
lagenase pretreatment were shown to increase the efficacy of
HKTs in TAM- and TAF-activated melanoma (Figure 9C and
D, respectively), pointing to a possible synergistic effect
whereas both agents previously showed multiple roles in the
TME.17–26

Role of HKTs on Immunosuppressive and
Stem-Like Cell Characteristics of B16F10
Melanoma Cells in Monotherapy or
Combined with TME-Remodeling Agents
(Metformin and Collagenase)
TAM- and TAF-activated melanoma cells exhibited higher
levels of all the immunosuppressive (TGFβ and CD47)
and stem-like cell (CD133) markers relative to
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Figure 7 Intracellular uptake of fluorescein-loaded TFs in nonactivated and TAM- or TAF-activated B16F10 melanoma cells (A). Mechanism of endocytic uptake of TFs in
nonactivated (B), TAM-activated (C), and TAF-activated (D) B16F10 melanoma cells. ns, not significant. *p<0.05; **p<0.01; **p<0.001; ****p<0.0001.

nonactivated melanoma cells (Figure 10A and B, respec
tively). It is well known that TGF-β can be secreted from
tumor cells, TAMs,64,65 and TAFs,66,67 promoting prolif
eration, angiogenesis, immunosuppression, ECM remodel
ing, invasion, and metastasis.111–115 In addition, TGF-β
has been reported to regulate cancer stemness and induce
the expression of stem-like cell markers like CD133.115–
117
CSCs can then secrete more TGF-β, regulating all
immunohallmarks in the tumor, including the expression
of CD47.118 This shows how the TME is highly orche
strated and that all the three markers are interrelated.
Treatment of TAM-activated cells with HKTs reduce
the levels of TGF-β, CD47, and CD133 (Figure 10A and
Figure S1A–C). This could be explained on the basis of
the previously reported role of HK in exhibiting an immu
nogenic effect in gastric cancer via inducing endoplasmic
reticulum stress, blocking epithelial–mesenchymal transi
tion, and suppressing calreticulin.119 A prophagocytic
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marker associated with poor prognosis of some cancer
types, calreticulin has been positively correlated with the
antiphagocytic CD47 for maintaining cellular homeostasis
by balancing pro- and antiphagocytic signals.120
Therefore, the suppressive effect observed for HK in our
study on CD47 could have been regulated indirectly via
calreticulin. Another possible explanation for the reduced
levels of CD47 in HK-treated cells is the downregulation
of TGF-β signaling: CD47 expression has been previously
reported to be associated with TGF-β expression.121
Moreover, HK possesses CSC-targeting potential,
reduces the proliferation of CD133+ CSCs, and
reverts the conferred resistance to chemotherapy in glio
blastoma multiforme and oral squamous- cell
carcinoma.122–124
Further improvement in the therapeutic outcome of
TAM-activated melanoma cells was observed upon pre
treatment with metformin. Metformin has been reported
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Figure 8 Cytotoxicity of HKTs in activated and nonactivated B16F10 melanoma
cells. *p<0.05; *; p<0.01; ***; p<0.001.

Dovepress

to reduce TGF-β expression and attenuate TGFβmediated tumorigenesis.26 It also possesses a repressing
role on tumor initiation, self-renewal, and chemoresis
tance conferred by the breast cancer stem
cells (BCSCs). Metformin was found to cause miR-708
mediated repression of the gene CD47 facilitating pha
gocytosis of BCSCs by macrophages.125 Metformin also
mediates the downregulation of CD133 in hepatocellular
carcinoma126 and pancreatic cancer,127,128 affecting
higher chemosensitivity.
In an opposite manner, pretreatment of TAM-activated
melanoma cells with collagenase produced an undesirable
impact. This could be explained by the previously reported
anti-inflammatory role of collagenase: it was found to
upregulate anti-inflammatory cytokines, IL10, and TGF-β
and downregulate the proinflammatory cytokines TNFα
and IL1β.129

Figure 9 Intracellular uptake of fluorescein-loaded TFs in nonactivated and TAM- or TAF-activated melanoma cells upon combination with TME remodeling agents
(metformin and collagenase) (A). Cytotoxicity of HKTs in nonactivated (B), TAM-activated (C), and TAF-activated (D) B16F10 melanoma cells upon combination with TME
remodeling agents (metformin and collagenase). *P<0.05; *; p<0.01.
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Figure 10 Role of HKTs on the immunosuppressive (TGFβ and CD47) and stem-like cell (CD133) markers of TAM-activated (A) and TAF-activated (B) B16F10 melanoma
cells. TGF-β concentration was analyzed with ELISA, while CD47 and CD133 were analyzed with WB. Bands for CD47, CD133, and β-actin proteins were visualized by
enhanced chemiluminescence (ECL Plus) and quantified relative to β-actin using densitometry and Molecular Analyst Software. Uncropped blots of CD47, CD133, and βactin proteins are provided in the supplementary materials (Figure S1A–C, respectively). *p<0.05; *****p<0.001; **p<0.0001.

Treatment of TAF-activated cells with HKTs
reduced levels of all the tested markers (Figure 10B and
Figure S1A–C). However, the combination therapy produced
detrimental effects on the level of the immunosuppressive and
stem-like cell characteristics of melanoma. While the effect of
collagenase pretreatment was not surprising, the detrimental
effect of metformin was not expected. Investigation of the
literature for a possible explanation revealed tha metformin
has a positive role on the secretion of TGF-β in supernatants of
4T1 triple-negative breast cancer cells.130

Conclusion
Atoxic HKTs were successfully fabricated using a simple,
scalable, green, modified heating method. Box–Behnken sur
face analysis proved to be an efficient tool to optimize the
HKT formulations. HKTs possessed uniform nanosize, high
negative charge, high EE%, and sufficient elasticity, and
provided sustained release of HK over 48 hours. Moreover,
HKTs reduce levels of TGF-β, CD47, and CD133, alleviating
the immunosuppressive and stem-like cell characteristics of
melanoma cells. Further improvement in therapeutic outcome
was observed upon pretreatment with metformin, while pre
treatment with collagenase produced an undesirable effect.
With the view that the TME is highly orchestrated, it is

International Journal of Nanomedicine 2021:16

necessary to investigate the role of the proposed topical
HKT therapy on other key players of the TME.
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